Search

Search Constraints

You searched for: Author/Creator Van Nueten, Luc

Search Results

1. [P2–211]: AMYLOID‐β42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID‐POSITIVE VERSUS AMYLOID‐NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT‐RISK FOR AD POPULATION. (1st July 2017)

2. Assessment of cognitive‐driven activity of daily living impairment in non‐demented Parkinson's patients. Issue 1 (15th October 2018)

3. Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. (9th February 2021)

4. Evaluating Potential QT Effects of JNJ‐54861911, a BACE Inhibitor in Single‐ and Multiple‐Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration‐QTc Analysis. (5th March 2018)

5. Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors. Issue 1 (December 2016)

6. O1‐10‐05: Pharmacodynamics of the Oral Bace Inhibitor JNJ‐54861911 in Early Alzheimer's Disease. (1st July 2016)

7. P1‐052: A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI‐PHOSPHO‐TAU ANTIBODY JNJ‐63733657 IN HEALTHY SUBJECTS. (1st July 2019)

8. P1‐230: MEMORY FUNCTION IS ASSOCIATED WITH TAU PATHOLOGY IN PARKINSON'S DISEASE. (1st July 2019)

9. P1‐257: LONGITUDINAL COMPARISON OF CSF BIOMARKERS OF NEURODEGENERATION IN PATIENTS WITH PROBABLE IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH). (1st July 2019)

10. P2‐011: Pharmacokinetic/Pharmacodynamic Modeling of CSF AB1‐40 Reduction in an Early Alzheimer's Disease Study of JNJ‐54861911, an Oral Bace1 Inhibitor. (1st July 2016)